People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Occulo Holdings LLC | — | Biotechnology | Series A | $12.8M | $462.7M | 2017 |
| SMOC Therapeutics, Inc. | — | Pharmaceuticals | Series A | $7.5M | $232.3M | 2017 |
| Red Oak Medicines Inc. | — | Pharmaceuticals | Seed | $2.1M | $79.9M | 2017 |
Yong Wang at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Yong Wang on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Hao Wu | 1 | 5 |
| Kevin Sprott | 1 | 1 |
| Shjiang Lu | 1 | 1 |
| Chris Bailey-Kellogg | 1 | 1 |
| Karl Griswold | 1 | 1 |
| Xiuyan Xu | 1 | 1 |
| Walter Huang | 1 | 1 |
| David Scadden, MD | 1 | 1 |
| Hongtao Li | 1 | 1 |
| Michael Franken | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.